SCHEMBL23979382

SCHEMBL23979382

Cc1cccc(NC(=O)NCc2ccc3nc(C)n(C4CCCC(=O)NC4=O)c(=O)c3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 9/20 0.51
CRBN Q96SW2 9/20 0.51
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
USP2 O75604 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GRM5 P41594 1/20 0.42
IKZF3 Q9UKT9 2/20 0.42
TNF P01375 1/20 0.42
IL1B P01584 1/20 0.42
GSPT1 P15170 4/20 0.42
GAA P10253 1/20 0.39
NAMPT P43490 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3647950 0.95 CRBN (0.57) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL12638509 0.89 DDB1 (0.47) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL23979418 0.88 DDB1 (0.49) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL23980066 0.84 DDB1 (0.54) DDB1CRBNMEN1KMT2ASMN1; SMN2
SCHEMBL23980077 0.84 DDB1 (0.45) DDB1CRBNMEN1KMT2AMAPT
SCHEMBL23979396 0.84 DDB1 (0.47) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL23979588 0.84 DDB1 (0.53) DDB1CRBNMEN1KMT2AIKZF3
SCHEMBL3653674 0.83 DDB1 (0.55) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL18595131 0.83 NPC1 (0.45) DDB1CRBNNPC1RAB9AMEN1
SCHEMBL3655629 0.83 CRBN (0.62) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885NPC1 1384/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885NPC1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.